GT Biopharma Inc. has announced that all holders of its Series L 10% Convertible Preferred Stock have agreed to waive their rights to redemption as provided in the stock's certificate of designation. The waivers, received from holders on several dates in September 2025, mean that Series L Preferred Stockholders will no longer be able to require the company to redeem their shares under the previously established terms. This modification impacts the rights of security holders and alters the conditions under which the preferred shares may be repaid or converted.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-015725), on September 26, 2025, and is solely responsible for the information contained therein.